Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells

Journal of Clinical Investigation

Volumn 104, Issue 2, 1999, Pages 173-180

  Dhodapkar, Madhav V ^a   Steinman, Ralph M ^a   Sapp, Mark ^a   Desai, Hema ^a   Fossella, Coraleen ^a   Krasovsky, Joseph ^a   Donahoe, Sean M ^a   Dunbar, P Rod ^b   Cerundolo, Vincenzo ^b   Nixon, Douglas F ^a   Bhardwaj, Nina ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOCYANIN; HLA A ANTIGEN; MATRIX PROTEIN; TETANUS TOXOID;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOMODULATION; MALE; MEMORY CELL; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0032754286     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI6909     Document Type: Article

References (31)

1. Raychaudhuri, S., and Rock, K.L. 1998. Fully mobilizing host defense: building better vaccines. Nat. Biotechnol. 16:1025-1031.
2. Banchereau, J., and Steinman, R.M. 1998. Dendritic cells and the control of immunity. Nature. 392:245-252.
3. Cella, M., Sallusto, F., and Lanzavecchia, A. 1997. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9:10-16.
4. Celluzzi, C.M., Mayordomo, J.I., Storkus, W.J., Lotze, M.T., and Falo, L.D., Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183:283-287.
5. Mayordomo, J.I., et al. 1997. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines, Stem Cells. 15:94-103.
6. Porgador, A., Snyder, D., and Gilboa, E. 3996. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:2918-2926.
7. Zitvogel, L., et al. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87-97.
8. Hsu, F.J., et al. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52-58.
9. Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A. 1996. Phase J clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate. 29:371-380.
10. Nestle, F.O., et al. 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-332.
11. Kundu, S.K., et al. 1998. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res. Hum. Retroviruses. 14:551-560.
12. Wen, Y.J., Ling, M., Bailey-Wood, R., and Lim, S.H. 1998. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin. Cancer Res. 4:957-962.
13. Schuler, G., and Steinman, R.M. 1997. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186;1183-1187.
14. Bender, A., Sapp, M., Schuler, G., Steinman, R.M., and Bhardwaj, N. 1996. Improved methods for the generation of dendritic cells from non-proliferating progenitors in human blood. J. Immunol. Methods. 196:121-135.
15. Altman, J.D., et al. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:94-96.
16. + memory T cells. J. Exp. Med. 186:859-865.
17. Larsson, M., et al. 1999. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of pol specific CD8+ T cells in chronically infected HIV-1 positive individuals. AIDS. 13:767-777.
18. Gotch, F., Rothbard, J., Howland, K., Townsend, A., and McMichael, A. 1987. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature. 326:881-882.
19. Bender, A., Bui, L.K., Feldman, M.A., Larsson, M., and Bhardwaj, N. 1995. Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. J. Exp. Med. 182:1663-1671.
20. Bhardwaj, N., et al. 1994. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. J. Clin. Invest. 94:797-807.
21. Dunbar, P.R., et al. 1998. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cyroroxic T lymphocytes from peripheral blood. Curr. Biol. 8:413-416.
22. Reddy, A., Sapp, M., Feldman, M., Subklewe, M., and Bhardwaj, N. 1997. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood. 90:3640-3646.
23. Zhou, L.-J., and Tedder, T.F. 1997. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc. Natl. Acad. Sci. USA. 93:2588-2592.
24. Curtis, J.E., Hersh, E.M., Harris, J.E., McBride, C., and Freireich, E.J. 1970. The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. Clin. Exp. Immunol. 6:473-491.
25. Pardoll, D.M. 1998. Cancer vaccines. Nat. Med. 4:525-531.
26. Zinkernagel, R.M., and Hengartner, H. 1997. Antiviral immunity. Immunol. Today. 18:258-260.
27. Rosenberg, S.A., et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321-327.
28. Clements-Mann, M.L., et al. 1998. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J. Infect. Dis. 177:1230-1246.
29. Wang, R., et al. 1998. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 282:476-480.
30. Ridge, J.P., Di Rosa, F., and Matzinger, P. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 393:474-478.
31. Steinman, R.M., and Germain, R.N. 1998. Antigen presentation and related immunological aspects of HIV-1 vaccines. AIDS. 12:S97-S112.